Sigma-Aldrich buys BioReliance for $350M
Avista Capital Partners is exiting its four-year-old investment in biopharmaceutical testing company BioReliance Holdings Inc., via a sale to Sigma-Aldrich […]
Say something
Avista Capital Partners is exiting its four-year-old investment in biopharmaceutical testing company BioReliance Holdings Inc., via a sale to Sigma-Aldrich […]